Combined hormonal contraception and venous thromboembolism

References

• Jick H, Jick S S, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–1593
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575–1582
   PubMed Web of Science ®Google Scholar
• Kemmeren I M, Algra A, Grobee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 1–7
   PubMed Web of Science ®Google Scholar
• Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet 1993; 353: 1167–1173
   Google Scholar
• Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185–191
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cardiovascular disease and use of oral and injectable contraceptives. Contraception 1998; 57: 315–324
   PubMed Web of Science ®Google Scholar
• RCOG. Venous thromboembolism and hormonal contraception, Guideline n° 40. 2004
   Google Scholar
• Rosendaal F R. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610–619
   PubMed Web of Science ®Google Scholar
• Winkler U H, Schindler A E, Endriket J, Düsterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 µg and 30 µg ethinylestradiol. Contraception 1995; 53: 75–84
   Web of Science ®Google Scholar
• Archer D F, Mammen E F, Grubb G S. The effects of a low-dose monophasic preparation of levonorgestrel and ethinylestradiol on coagulation and other hemostatic factors. Am J Obstet Gynecol 1999; 181: S63–S66
   PubMed Web of Science ®Google Scholar
• Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, et al. Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995; 346: 1593–1596
   PubMed Web of Science ®Google Scholar
• Mohllajee A P, Curtis K M, Martins S L, Peterson H B. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006; 73: 166–178
   PubMed Web of Science ®Google Scholar
• Spannagl M, Heinemann L AJ, DoMinh T, et al. Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study. Thromb Journal 2005; 3: 1–10
   PubMedGoogle Scholar
• Vandenbroucke J P, Rosing J, Bloemenkamp K WM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527–1535
   PubMed Web of Science ®Google Scholar
• Hannaford P. The collection and interpretation of epidemiological data about the cardiovascular risks associated with the use of steroid contraceptives. Contraception 1998; 57: 137–142
   PubMed Web of Science ®Google Scholar
• Winkler U H. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000; 62: 11S–20S
   PubMed Web of Science ®Google Scholar
• Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036–2040
   PubMed Web of Science ®Google Scholar
• Tans G, Van Hylckama A, Thomassen M CLGD, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465–470
   PubMed Web of Science ®Google Scholar
• Gris JCh, Jamin Ch, Benifla J L, et al. APC resistance and third-generation oral contraceptives. Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum Reprod 2001; 16: 3–8
   PubMed Web of Science ®Google Scholar
• Heinemann L AJ, Kluft C, Spannagl M, Maat M PM. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception 2002; 66: 297–304
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 2002; 81: 482–490
   PubMed Web of Science ®Google Scholar
• Van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin—a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004; 190: 332–337
   PubMed Web of Science ®Google Scholar
• van Vliet H A, Frolich M, Christella M, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005; 20: 563–568
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye I A, Vasilakis-Scaramozza C, Jick S S. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190–1195
   PubMed Web of Science ®Google Scholar
• Suissa S, Blais L, Spitzer W O, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–146
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national case-control study. Contraception 2002; 65: 187–196
   PubMed Web of Science ®Google Scholar
• Farmer R D, Lawrenson R A, Todd I C, et al. A comparison of the risks of venous thromboembolism disease in association with different combined oral contraceptives. Br J Pharmacol 2000; 49: 580–590
   Web of Science ®Google Scholar
• Kenneth A, Bauer K A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367–373
   PubMed Web of Science ®Google Scholar
• Hennessy S, Berlin I A, Kinman I L, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2002; 64: 125–133
   Web of Science ®Google Scholar
• Sidney S, Petitti D B, Soff G A, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004; 70: 3–10
   PubMed Web of Science ®Google Scholar
• Timmer C J, Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233–242
   PubMed Web of Science ®Google Scholar
• Lewis M A, Heinemann L AJ, MacRae K D, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
   PubMed Web of Science ®Google Scholar
• Abrams L S, Skee D, Natarajan J, et al. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002; 77: S3–S12
   PubMed Web of Science ®Google Scholar
• Smallwood G H, Meador M, Lenihan J P, et al. Efficacy and safety of transdermal contraceptive system. Obstet Gynecol 2001; 98: 799–805
   PubMed Web of Science ®Google Scholar
• FDA Updates Labeling for Ortho Evra Contraceptive Patch. FDA Press Release, November 10, 2005. Available at: http://www.fda.gov/bbs/topics/news/2005/NEW01262.html
   Google Scholar
• Jick S S, Kaye J A, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 µg ethinyl estradiol. Contraception 2006; 73: 223–228
   PubMed Web of Science ®Google Scholar
• Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326: 257
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Safety 2004; 27: 1001–1018
   PubMed Web of Science ®Google Scholar
• Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427–1429
   PubMed Web of Science ®Google Scholar
• Seaman H E, Vries C S, Farmer R D. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinylestradiol: a nested cohort analysis and case-control study. Hum Reprod 2003; 18: 522–526
   PubMed Web of Science ®Google Scholar
• CSM. Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Probl Pharmacovigilance 2002; 28: 9–10
   Google Scholar
• Winkler U H, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either 2 mg chlormadinone acetate or 150 mcg desogestrel. Eur J Contracept Reprod Health Care 1999; 4: 145–154
   PubMed Web of Science ®Google Scholar
• Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 2002; 22: 221–231
   Web of Science ®Google Scholar
• Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70: 437–441
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products. CPMP Public assessment report: Combined oral contraceptives and venous thromboembolism, Doc. Ref: EMEA/CPMP/2201/01/en/Final
   Google Scholar
• Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives—an approach to specifying rates. Eur J Epidem 2005; 20: 509–516
   PubMed Web of Science ®Google Scholar
• Colditz G A. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses Health Study. Ann Intern Med 1994; 120: 821–826
   PubMed Web of Science ®Google Scholar
• Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25-year follow up cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96–100
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva 2000
   Google Scholar
• World Health Organization. Medical Eligibility Criteria for Contraceptive Use3rd ed. WHO, Geneva 2004
   Google Scholar
• British Society for Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704–715
   PubMed Web of Science ®Google Scholar
• Santamaría A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 2001; 86: 965–971
   PubMedGoogle Scholar
• Vandenbroucke J P, van der Meer F, Helmerhorst F M, Rosendaal F R. Factor V Leiden: should we screen oral contraceptives users in pregnant women?. BMJ 1996; 313: 1127–1130
   PubMed Web of Science ®Google Scholar
• Girolami A, Tormene D, Gavaso S, et al. Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients homozygous and 35 heterozygous. J Thromb Thrombolysis 2004; 17: 145–149
   PubMed Web of Science ®Google Scholar
• Nightingale A L, Lawrenson R A, Simpson E L, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5: 265–274
   PubMedGoogle Scholar